Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label immunobridging study of 9-valent HPV vaccine (V503) in Chinese females aged 9–45 years
CTR20190574Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC), Vulval carcinoma, vaginal cancer, anal cancer, cervical intraepithelial neoplasia (CIN), sponsored by Merck & Co.. Started Mar 2019; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
Cervical Cancer (CC)Vulval carcinomavaginal canceranal cancercervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on CTR20190574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190574.